Imidazoles Patents (Class 514/396)
-
Publication number: 20120329834Abstract: The present invention relates to the use of compounds of general formula (I): (I) for the preparation of medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as mitochondrial diseases.Type: ApplicationFiled: April 15, 2010Publication date: December 27, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITY OF PITTSBURGH, INSTITUT CURIEInventors: Marc Blondel, Elodie Couplan, Jean-Paul Di Rago, Daniel Dauzonne, Michael Palladino, Alicia Celotto
-
Patent number: 8338421Abstract: The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: December 25, 2012Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn
-
Patent number: 8338470Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: July 3, 2012Date of Patent: December 25, 2012Assignee: Hospira, Inc.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Patent number: 8334293Abstract: The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.Type: GrantFiled: November 4, 2009Date of Patent: December 18, 2012Assignee: Eli Lilly and CompanyInventor: Sandaruwan Geeganage
-
Patent number: 8334316Abstract: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.Type: GrantFiled: February 9, 2009Date of Patent: December 18, 2012Assignee: ACEA Biosciences, Inc.Inventors: Xiao Xu, Haoyun An, Xiaobo Wang
-
Publication number: 20120316210Abstract: This invention recites topical formulations comprising demiditraz, fipronil, an acid modifier, at least one veterinarily acceptable carrier, and optionally, at least one antioxidant for treating a parasitic infection or infestation in animals.Type: ApplicationFiled: January 4, 2011Publication date: December 13, 2012Applicant: PFIZER INC.Inventors: Nathan Anthony Logan Chubb, Guy Francis de Rose, Sunil Thomas Kumar Narishetty
-
Patent number: 8329685Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.Type: GrantFiled: January 16, 2003Date of Patent: December 11, 2012Assignee: North West UniversityInventor: Petrus Johannes Meyer
-
Patent number: 8329738Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.Type: GrantFiled: June 12, 2007Date of Patent: December 11, 2012Assignee: Merck Patent Gesellschaft mit Beschränkter HaftungInventors: Gerard Moinet, Dominique Marais, Sophie Hallakou-Bozec, Christine Charon
-
HYPERBRANCHED POLYESTER WITH A HYDROPHOBIC NUCLEUS FOR SOLUBILIZING POORLY SOLUBLE ACTIVE SUBSTANCES
Publication number: 20120309626Abstract: The invention provides a composition comprising an active ingredient with a maximum solubility in water at 20° C. of 10 g/l, and a hyperbranched polyester based on a hydrophobic dicarboxylic acid and a trifunctional alcohol. The invention further relates to the hyperbranched polyester mentioned, to a process for preparation thereof and to the use thereof for solubilizing an active ingredient with a maximum solubility in water at 20° C. of 10 g/l in aqueous solutions.Type: ApplicationFiled: December 15, 2010Publication date: December 6, 2012Applicant: BASF SEInventors: Holger Türk, Monika Haberecht, Hiroe Yamada, Bernd Bruchmann, Daniel Schönfelder, Michael Ishaque, Ulrike Troppmann, Joachim Clauss, Chee Chin Liew -
Publication number: 20120309804Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Alpha Synergy Development Inc.Inventor: Gerald Horn
-
Publication number: 20120309720Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Alpha Synergy Development Inc.Inventor: Gerald Horn
-
Patent number: 8324260Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: GrantFiled: May 14, 2012Date of Patent: December 4, 2012Assignee: Hospira, Inc.Inventors: Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis James Stalker, Edward Koo
-
Patent number: 8324401Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A1QA2-; Q is a bond, —C(?O)—, —OC(O)—, —C(?O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(?O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.Type: GrantFiled: August 18, 2009Date of Patent: December 4, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, Bin Jiang
-
Publication number: 20120288566Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.Type: ApplicationFiled: October 5, 2010Publication date: November 15, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Michael Friedman, Doron Steinberg, Irith Gati
-
Patent number: 8309591Abstract: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition provides a rapid onset of action while having low irritation potential in the oral mucosa.Type: GrantFiled: November 24, 2010Date of Patent: November 13, 2012Assignee: Orion CorporationInventors: Mirja Huhtinen, Piritta Koistinen, Lasse Leino, Maria Rantala, Helena Kaukinen, Kaija Af Ursin
-
Patent number: 8304402Abstract: A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.Type: GrantFiled: May 5, 2005Date of Patent: November 6, 2012Assignee: Binyarco, LLCInventor: Jeffrey E. Binder
-
Patent number: 8304419Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.Type: GrantFiled: June 5, 2008Date of Patent: November 6, 2012Assignee: GlaxoSmithKline LLCInventors: Pek Yoke Chong, Andrew James Peat, Paul Richard Sebahar, Michael Youngman, Huichang Zhang
-
Publication number: 20120276182Abstract: The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Inventors: James R. Baker, JR., Mary R. Flack, Susan M. Ciotti, Joyce A. Sutcliffe
-
Publication number: 20120277241Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: July 10, 2012Publication date: November 1, 2012Applicant: GALDERMA LABORATORIES, INC.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 8299108Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: GrantFiled: September 29, 2003Date of Patent: October 30, 2012Assignee: Novartis AGInventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
-
Patent number: 8299102Abstract: The present invention relates to heteroarylcyclopropanecarboxamides of the formula I, in which Het, X, Ra, Rb, Rc, Rd, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.Type: GrantFiled: June 17, 2009Date of Patent: October 30, 2012Assignee: SanofiInventors: Hartmut Strobel, Paulus Wohlfart, Gerhard Zoller, David William Will
-
Patent number: 8293282Abstract: Disclosed is a wood preservative composition comprising micronized copper and copper-amine complex, wherein the copper component of the copper amine complex is from about 5% to about 50% by weight, based upon the total weight of copper in the composition. The copper amine complex serves to avoid wood surface “chalking” that is otherwise attributable to the presence of micronized copper in copper-based slurries used to treat wood products. In addition, the copper-amine complex enhances the antimicrobial efficacy of the composition when used in wood treatment applications by facilitating cell wall penetration of the treated wood.Type: GrantFiled: February 11, 2009Date of Patent: October 23, 2012Assignee: Arch Wood Protection, Inc.Inventor: Jayesh P. Patel
-
Patent number: 8288562Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: May 25, 2010Date of Patent: October 16, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Publication number: 20120258061Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid in combination with 0.0001% to about 50% of at combination of retinoid hoosters.Type: ApplicationFiled: June 21, 2012Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Patent number: 8283350Abstract: The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: October 9, 2012Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn
-
Publication number: 20120252820Abstract: Methods of identifying compounds that potentiate the activity of antifungal agents, potentiators identified by these methods, and methods of using potentiators to treat fungal infections are disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 4, 2012Applicant: NORTHEASTERN UNIVERSITYInventors: Kim Lewis, Michael David Lafleur
-
Patent number: 8277688Abstract: This invention relates to galvanic aluminum alloy powder-pigments coated with a semi-conducting corrosion inhibiting oxide and the process for preparing said coated powder-pigments in combination with film-forming binders for coating metal substrates to inhibit corrosion. The coated aluminum alloy powder-pigments are electrically active and prevent corrosion of metals which are more cathodic (electropositive) than the aluminum alloy pigments.Type: GrantFiled: July 27, 2011Date of Patent: October 2, 2012Assignee: The United States of America as represented by the Secretary of the NavyInventors: Craig Matzdorf, William Nickerson
-
Patent number: 8263634Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: November 9, 2010Date of Patent: September 11, 2012Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
-
Patent number: 8262938Abstract: Chromate-free corrosion-inhibiting coating compositions comprising film-forming binders and galvanic aluminum alloy powders prepared in an oxygen (oxidizing), nitrogen (inert) or nitrogen-hydrogen (reducing) atmosphere having particle sizes ranging up to 100 microns. The aluminum alloy powders having the formula: aluminum-zinc-X (AlZnX) wherein X is an element selected from the group consisting of indium, gallium, tin and bismuth. Improvement in corrosion protection is obtained by the addition of chemical inhibitors such as an azole or talcite clay to the coating which further inhibits the self-corrosion of the aluminum alloy and extends the corrosion protection of the metal substrate being protected.Type: GrantFiled: January 21, 2011Date of Patent: September 11, 2012Assignee: The United States of America, as represented by the Secretary of the Navy.Inventors: Craig Matzdorf, William Nickerson
-
Publication number: 20120220454Abstract: Coating compositions and methods of use, allowing for improved water and/or nutrient usage by seeds, plants, shrubs, and vegetation, among others, are disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 30, 2012Applicant: RHODIA OPERATIONSInventors: Zhiyun Chen, Jean-Christophe Castaing, PengFei JI, Galder Cristobal
-
Patent number: 8247429Abstract: The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or mercapto optionally having a substituent, Xa, Xb, Xc and Xd are each a carbon atom or a nitrogen atom, provided that any one or two of Xa, Xb, Xc and Xd is/are nitrogen atom(s), m is 0 to 2, and rings A to C are each a ring optionally having substituent(s), or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.Type: GrantFiled: December 27, 2007Date of Patent: August 21, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Osamu Uchikawa, Tatsuki Koike, Takafumi Takai, Yasutaka Hoashi
-
Publication number: 20120208858Abstract: The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.Type: ApplicationFiled: February 14, 2012Publication date: August 16, 2012Applicant: ALLERGAN, INC.Inventors: Stuart D. Shanler, Christopher Powala
-
Patent number: 8242151Abstract: The present invention provides a PPAR ? agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) (wherein R1 represents lower alkyl optionally having substituent(s) or the like, R2 and R3 are the same or different and each represents lower alkyl optionally having substituent(s) or the like, R4 and R5 are the same or different and each represents a hydrogen atom or the like, Q1-Q2-Q3 represents CH?CH—CH?CH or the like, Y represents a single bond or the like, Z1-Z2 represents C?CR13 (wherein R13 represents a hydrogen atom or the like), or the like, and A represents —COOH or the like), or a pharmaceutically acceptable salt thereof and the like.Type: GrantFiled: February 7, 2008Date of Patent: August 14, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Arata Yanagisawa, Takeshi Kuboyama, Seiji Aratake, Kazuki Hemmi, Kimihisa Ueno, Michihiko Suzuki, Masahiro Matsubara, Kozo Yao, Akinori Hamaguchi, Yukihito Tsukumo
-
Patent number: 8242158Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: January 4, 2012Date of Patent: August 14, 2012Assignee: Hospira, Inc.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Publication number: 20120202865Abstract: A compound having selective modulating activity at the alpha 2B and or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein R1-R6 is independently selected from the group consisting of H, C1-6 alkyl, halogen, CH2OH, CH2N(R7)2, CH2CN, C(O)R8, CF3, and aryl; wherein R7 is H or C1-6 alkyl; and R8 is H, C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.Type: ApplicationFiled: April 24, 2012Publication date: August 9, 2012Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Smita S. Bhat, Ken Chow
-
Publication number: 20120202864Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine at acidic pH and extremely low concentrations.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Publication number: 20120202863Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine at near alkaline pH and extremely low concentrations.Type: ApplicationFiled: February 3, 2011Publication date: August 9, 2012Inventor: Gerald Horn
-
Publication number: 20120196908Abstract: This invention describes new antifungal compounds that are aralkyl benzyl ethers of the formula (I): wherein: Ar represents aryl, imidazolil, 1,2,4-triazolyl, benzimidazolil; R1, R2, R4 and R5 are independently hydrogen, halogen, C1-6 alkyl; R3 represents halogen, C1-6alkyl or O—R? where R? represents hydrogen or lower alkyl; R6 represents aryl, substituted aryl, trifluoromethyl, trichloromethyl or O—R? where R? represents hydrogen or lower alkyl; being the substituents of the aryl a halogen or a radical tetrazolyl; n and m represent independently an integer between 0 and 5; With the proviso that when Ar is imidazolil, R3 is chlorine, R6 is p-phenyl and R1, R2, R4 and R5 are hydrogen, n must be different from 2. When n and m are not 0 and 1, R3 or R6 can be represented by substituents not necessarily equal.Type: ApplicationFiled: August 27, 2010Publication date: August 2, 2012Applicant: BIOLAB SANUS FARMACEUTICA LTDA.Inventors: Artur Franz Keppler, Sérgio Luiz Sacurai, Marcio Henrique Zaim, Carlos Eduardo da Costa Touzarim
-
Publication number: 20120196905Abstract: Methods and small molecule compounds for smoking and CNS disease harm reduction are provided.Type: ApplicationFiled: August 5, 2011Publication date: August 2, 2012Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTEInventor: John R. CASHMAN
-
Publication number: 20120196874Abstract: Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Inventors: David WATT, Chunming Liu, Vitaliy M. Sviripa, Wen Zhang
-
Publication number: 20120196819Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said compositon dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.Type: ApplicationFiled: January 4, 2012Publication date: August 2, 2012Applicant: NEWMARKET PHARMACEUTICALS LLCInventors: David ROCK, Mark RIDALL
-
Patent number: 8232304Abstract: A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. In a representative example, the low potency anti-inflammatory steroid has the following structure: wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R1 and R2 taken together can be C3-C10 cycloalkyl; and R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.Type: GrantFiled: October 23, 2003Date of Patent: July 31, 2012Assignee: G & R Pharmaceuticals, LLCInventors: Jay A. Goldstein, Michael Rothman, Whe-Yong Lo
-
Patent number: 8232305Abstract: Anti-microbial compositions comprising certain imidazolium ionic liquids and non-ionic or anionic surfactants and methods of using said compositions in the preservation of personal care and cosmetic applications are provided.Type: GrantFiled: June 8, 2007Date of Patent: July 31, 2012Assignee: BASF SEInventors: Stewart Todd Elder, Andrea Preuss, Kai-Uwe Schöning, Karin Mühlbauer
-
Publication number: 20120190719Abstract: Disclosed herein is a method of treating compulsive disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist.Type: ApplicationFiled: August 26, 2010Publication date: July 26, 2012Applicant: ALLERGAN, INC.Inventors: Daniel W. Gil, John E. Donello, Lauren M.B. Luhrs
-
Patent number: 8227497Abstract: The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: June 22, 2011Date of Patent: July 24, 2012Assignee: Theravance, Inc.Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Robert Murray McKinnell
-
Publication number: 20120178769Abstract: The present invention discloses novel compounds for inhibiting eEF2 kinase and methods of use thereof.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Applicant: The University of Medicine and DentistryInventor: Alexey G. Ryazanov
-
Publication number: 20120178728Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.Type: ApplicationFiled: March 21, 2012Publication date: July 12, 2012Applicant: BASF SEInventors: Nathalie Bouillo, Marianna Pierobon, Ralf Widmaier, Rainer Dobrawa, Kathrin Meyer-Böhm, Ronald Frans Maria Lange
-
Publication number: 20120178724Abstract: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Joseph Michael Sprafka, II, Jose Mauro Goulart-Brum
-
Publication number: 20120177585Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.Type: ApplicationFiled: January 6, 2012Publication date: July 12, 2012Applicant: ALLERGAN, INC.Inventors: Stuart D. Shanler, Andrew Ondo
-
Publication number: 20120165347Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Applicant: ASTRAZENECA ABInventors: Gabor Csjernyik, Sofia Karlström, Annika Kers, Karin Kolmodin, Martin Nylöf, Liselotte Öhberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg